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Background: Initiation of adjuvant chemotherapy within 6–12weeks after mastectomy is recommended
by guidelines. The aim of this population-based study was to investigate whether immediate breast recon-
struction (IBR) after mastectomy reduces the likelihood of timely initiation of adjuvant chemotherapy.
Methods: All patients with breast cancer who had undergone mastectomy and adjuvant chemotherapy
between 2012 and 2016 in the Netherlands were identified. Time from surgery to adjuvant chemotherapy
was categorized as within 6weeks or after more than 6weeks, within 9weeks or after more than 9weeks,
and within 12weeks or after more than 12weeks. The impact of IBR on the initiation of adjuvant
chemotherapy for these three scenarios was estimated using propensity score matching to adjust for
treatment by indication bias.
Results: A total of 6300 patients had undergone primary mastectomy and adjuvant chemotherapy, of
whom 1700 (27⋅0 per cent) had received IBR. Multivariable analysis revealed that IBR reduced the like-
lihood of receiving adjuvant chemotherapy within 6weeks (odds ratio (OR) 0⋅76, 95 per cent c.i. 0⋅66 to
0⋅87) and 9weeks (0⋅69, 0⋅54 to 0⋅87), but not within 12weeks (OR 0⋅75, 0⋅48 to 1⋅17). Following propen-
sity score matching, IBR only reduced the likelihood of receiving adjuvant chemotherapy within 6weeks
(OR 0⋅95, 0⋅90 to 0⋅99), but not within 9weeks (OR 0⋅97, 0⋅95 to 1⋅00) or 12weeks (OR 1⋅00, 0⋅99 to 1⋅01).
Conclusion: Postmastectomy IBRmarginally reduced the likelihood of receiving adjuvant chemotherapy
within 6weeks, but not within 9 or 12weeks. Thus, IBR is not contraindicated in patients who need
adjuvant chemotherapy after mastectomy.
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Introduction
Breast cancer is the most commonly diagnosed malignant
cancer among women1. Despite advancements in diagnos-
tics and systemic treatment, up to one-third of patients
with breast cancer undergo mastectomy as the first sur-
gical treatment to achieve local control2. Adjuvant sys-
temic treatment, including chemotherapy, reduces the risk
of distant recurrence and breast cancer mortality3. In the
Netherlands, 6weeks is the maximum time limit aimed
for between surgery and initiation of adjuvant chemother-
apy, as recommended by the European Society for Medical
Oncology4 (ESMO) and the Netherlands Society for Plas-
tic Surgery5,6.
Several studies7–12 have reported that delayed initia-
tion of adjuvant chemotherapy is associated with lower
overall and recurrence-free survival. The recommended
acceptable maximum delay, however, varies from 7 to
12weeks. There still is no international consensus on
the definition of an unacceptable delay, but all guidelines
advocate that initiation of adjuvant chemotherapy should
not be delayed unnecessarily, as this may have a negative
impact on survival, specifically in patients at higher risk of
recurrence9,10,12.
The addition of immediate breast reconstruction (IBR)
to mastectomy could result in preoperative delay owing to
more complex logistic coordination of the operation. After
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surgery, a delay could be the result of longer recovery, as
IBR may increase the risk of postoperative complications,
even though reports on the risk of adverse events are
conflicting13–16.
In the past decade, an increasing number of women
have undergone IBR after mastectomy2,17,18. IBR is gen-
erally associated with good aesthetic results and less neg-
ative psychological impact on the patient, as it involves
fewer operations and hospital admissions compared with
breast reconstruction at a later time19–21. Owing to the lack
of consensus on timing of adjuvant chemotherapy, physi-
cians remain cautious in recommending IBR when adju-
vant chemotherapy is part of the preoperative treatment
plan22.
Most previous studies16,23 on the possible delaying
impact of postmastectomy IBR have been single-centre
studies with weak methodology and no adjustment for
treatment by indication bias. A systematic review24 from
2015 concluded that IBR does not delay time from surgery
to adjuvant chemotherapy to a clinically relevant extent,
although the included studies showed strongly contra-
dictory results. Moreover, a cut-off point of 12weeks to
initiation of adjuvant treatment was used, whereas current
European guidelines4 recommend 6weeks. Furthermore,
it seems likely that there may be an underlying reason
why some patients have IBR and others do not, giving
rise to treatment by indication bias when comparing the
outcomes of these two groups.
The aim of the present nationwide population-based
study was to investigate the extent to which postmastec-
tomy IBR reduces the likelihood of timely initiation of
adjuvant chemotherapy compared with mastectomy alone,
while also adjusting for confounding by indication.
Methods
Prospectively collected data from theNABONBreast Can-
cer Audit (NBCA) database were used. The NBCA was
started in 2011 and is an initiative from the National
Breast Cancer Organization Netherlands (NABON), the
Netherlands Comprehensive Cancer Organization and the
Dutch Institute for Clinical Auditing. The NBCA col-
lects anonymized data on clinicopathological characteris-
tics, diagnostics and treatment modalities in a database
from all hospitals in theNetherlands. It includes all patients
diagnosed with ductal carcinoma in situ (DCIS) or inva-
sive breast cancer treated surgically since 2012. TheNBCA
aims to monitor the quality of breast cancer care and to
provide feedback to participating hospitals to stimulate
and facilitate quality improvement25. No formal consent is
required for this type of study from an ethics committee
in the Netherlands according to Central Committee on
Research involving Human Subjects.
Patient population
All women diagnosed with invasive breast cancer between
2012 and 2016 who had undergone primary mastectomy
with or without IBR followed by adjuvant chemotherapy
were identified from the NBCA database. IBR was defined
as a reconstruction performed by a plastic surgeon on the
same day as the mastectomy. Women who had received
systemic neoadjuvant treatment, had undergone lumpec-
tomy as initial surgery or had a re-excision were excluded
from the analysis. Patients who had received another adju-
vant therapy before the initiation of adjuvant chemother-
apy, and those with a missing date of operation or adjuvant
chemotherapy were also excluded.
Outcomes
The primary outcome was whether the patient received
adjuvant chemotherapy within a specific time interval after
surgery. Time to adjuvant chemotherapy was analysed with
three different cut-off values: within 6weeks or after more
than 6weeks, within 9weeks or after more than 9weeks,
and within 12weeks or after more than 12weeks. These
cut-offs were chosen based on the currently recommended
starting point according to Dutch and ESMO guidelines,
and on previous literature demonstrating that a clinical
impact is found when adjuvant chemotherapy is started
later than 7–12weeks, indicating the importance of ini-
tiating adjuvant chemotherapy at least within this time
period4,7–12.
Confounders
Potential confounders included in analyses were year of
diagnosis, age, WHO performance status26, presence of
DCIS, histological type, receptor status, tumour stage
according to the seventh edition of AJCC27, sentinel node
biopsy, axillary lymph node dissection (ALND), hospital
transfer between site for surgery and that for adjuvant
chemotherapy, and annual number of patients operated on
for breast cancer at the hospital (hospital volume). Data
regarding reconstruction at a later time, rather than IBR,
are not registered in the NBCA and could therefore not be
included.
Statistical analysis
Statistical differences for all possible confounders between
women who had mastectomy alone and those who had
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mastectomy plus IBR were determined using χ2 tests. All
tests were two-sided, and P< 0⋅050 was considered statis-
tically significant. Multivariable logistic regression analysis
was used to determine the likelihood that women who had
undergone IBR received adjuvant chemotherapy within
6, 9 and 12weeks, when adjusted for the confounders.
There may, however, be an underlying reason why patients
have IBR, so that not all women are equally likely to
receive IBR, for example because of a different type of
tumour or age of the patient, introducing a treatment by
indication bias. Thus, propensity score matching (PSM)
was performed, including all available patient and tumour
characteristics to adjust for treatment by indication bias.
Use of PSM ensures that patients from both cohorts are
matched and have the same likelihood of receiving IBR,
given certain patient and tumour characteristics. For each
pair, one patient did and one did not undergo IBR; this is
essential to estimate the true treatment effect on an out-
come in observational studies28,29. Statistical analyses were
performed with SPSS® version 24 (IBM, Armonk, New
York, USA).
Results
In the selected time interval, 6300 women were diagnosed
with invasive breast cancer and met the eligibility criteria.
Of these, 4600 patients (73⋅0 per cent) underwent mastec-
tomy alone and 1700 patients (27⋅0 per cent) had postmas-
tectomy IBR. Of the women who had IBR, 91⋅2 per cent
had received an implant-based reconstruction (including
tissue expanders).
The proportion of women who had postmastectomy IBR
decreased with patient age and increased over time (Fig. 1).
Patients who underwent IBR were younger at diagnosis,
more often had a WHO status of 0, or were diagnosed
with no special type of histology, DCIS component and
tumour stage I than women who had mastectomy alone
(Table 1). There was no difference in receptor status or dif-
ferentiation grade between the two groups. Of women who
had postmastectomy IBR, the proportions that underwent
sentinel node biopsy, transferred hospital between surgery
and adjuvant chemotherapy, or were treated in a hospital
with surgical volume exceeding 250 patients annually were
also higher compared with those of women who had mas-
tectomy alone. However, the proportion that had ALND
was lower in women who underwent postmastectomy IBR
(Table 1).
Time to adjuvant chemotherapy
The median (i.q.r.) time from surgery to adjuvant
chemotherapy in women who had postmastectomy IBR
Fig. 1 Proportion of patients having immediate breast recon-
struction in relation to year of diagnosis and age
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was 36 (29–47) days, compared with 34 (28–44) days
in those who had mastectomy alone (Table 2). Adjuvant
chemotherapy was initiated within 6weeks in more than
two-thirds of patients, and the vast majority received
adjuvant chemotherapy within 9 and 12weeks. The total
proportion of patients who received adjuvant chemother-
apy within 6, 9 and 12weeks did not differ over time
(2012–2016: P= 0⋅282, P= 0⋅128 and P= 0⋅052 respec-
tively) (Fig. 2).
Unmatched multivariable analyses
Multivariable analysis revealed that patients who had
undergone IBR were less likely than those having mas-
tectomy alone to receive adjuvant chemotherapy within
6weeks (odds ratio (OR) 0⋅76, 95 per cent c.i. 0⋅66 to 0⋅87;
P< 0⋅001) or 9weeks (OR 0⋅69, 0⋅54 to 0⋅87; P= 0⋅002)
of surgery (Table 3). However, IBR had no association with
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Table 1 Baseline characteristics of patients who had
mastectomy alone or immediate breast reconstruction after
mastectomy and received adjuvant chemotherapy
Mastectomy
alone
(n=4600)
IBR after
mastectomy
(n=1700) P*
Year of diagnosis <0⋅001
2012 1282 (27⋅9) 290 (17⋅1)
2013 1113 (23⋅5) 365 (21⋅5)
2014 987 (21⋅5) 378 (22⋅2)
2015 690 (15⋅0) 411 (24⋅2)
2016 528 (11⋅5) 256 (15⋅1)
Age (years) <0⋅001
<40 304 (6⋅6) 295 (17⋅4)
40–49 1081 (23⋅5) 578 (34⋅0)
50–59 1506 (32⋅7) 578 (34⋅0)
60–69 1409 (30⋅6) 233 (13⋅7)
≥70 300 (6⋅5) 16 (0⋅9)
WHO performance status 0⋅001
0 4126 (89⋅7) 1572 (92⋅5)
1 450 (9⋅8) 116 (6⋅8)
≥2 24 (0⋅5) 12 (0⋅7)
Histology <0⋅001
No special type 3580 (77⋅8) 1414 (83⋅2)
Lobular 731 (15⋅9) 168 (9⋅9)
Both/other 289 (6⋅3) 118 (6⋅9)
DCIS component <0⋅001
No 2241 (48⋅7) 623 (36⋅6)
Yes 2359 (51⋅3) 1077 (63⋅4)
Receptor status 0⋅071
Triple-negative 695 (15⋅1) 223 (13⋅1)
HER2-neu+ 1053 (22⋅9) 405 (23⋅8)
HR+ and HER2− 2727 (59⋅3) 1038 (61⋅1)
Unknown 125 (2⋅7) 34 (2⋅0)
Differentiation grade 0⋅987
Well 431 (9⋅4) 161 (9⋅5)
Moderate 2136 (46⋅4) 791 (46⋅5)
Poor 2033 (44⋅2) 748 (44⋅0)
Tumour stage <0⋅001
I 1036 (22⋅5) 735 (43⋅2)
IIa 1542 (33⋅5) 632 (37⋅2)
IIb 856 (18⋅6) 200 (11⋅8)
III 1128 (24⋅5) 128 (7⋅5)
IV 38 (0⋅8) 5 (0⋅3)
Sentinel node biopsy <0⋅001
No 1439 (31⋅3) 131 (7⋅7)
Yes 3161 (68⋅7) 1569 (92⋅3)
ALND <0⋅001
No 2303 (50⋅1) 1265 (74⋅4)
Yes 2297 (49⋅9) 435 (25⋅6)
Hospital transfer 0⋅030
No 4466 (97⋅1) 1632 (96⋅0)
Yes 134 (2⋅9) 68 (4⋅0)
Table 1 Continued
Mastectomy
alone
(n=4600)
IBR after
mastectomy
(n=1700) P*
Hospital volume of surgery
(no. of patients)
< 0⋅001
1–99 223 (4⋅8) 29 (1⋅7)
100–149 1036 (22⋅5) 263 (15⋅5)
150–199 978 (21⋅3) 253 (14⋅9)
200–249 478 (10⋅4) 236 (13⋅9)
≥250 1885 (41⋅0) 919 (54⋅1)
Values in parentheses are percentages. IBR, immediate breast reconstruc-
tion; DCIS, ductal carcinoma in situ; HR+, hormone receptor-positive;
ALND, axillary lymph node dissection. *χ2 test.
Table 2 Time from surgery to adjuvant chemotherapy, and
proportion of patients receiving adjuvant chemotherapy within
6, 9 and 12 weeks
Mastectomy
alone
(n=4600)
IBR after
mastectomy
(n=1700)
Time from surgery to adjuvant
chemotherapy (days)*
34 (28–44) 36 (29–47)
No. of patients receiving adjuvant
chemotherapy
Within 6weeks 3297 (71⋅7) 1145 (67⋅4)
Within 9weeks 4304 (93⋅6) 1564 (92⋅0)
Within 12weeks 4509 (98⋅0) 1669 (98⋅2)
Values in parentheses are percentages unless indicated otherwise; *values
are median (i.q.r.). IBR, immediate breast reconstruction.
receiving adjuvant chemotherapy within 12weeks (OR
0⋅75, 0⋅48 to 1⋅17; P= 0⋅205).
Although not the focus of this study, analyses of predic-
tive confounders demonstrated that, amongst other fac-
tors, patients who had a sentinel node biopsy or ALND
were less likely to receive adjuvant chemotherapy within
6 and 9weeks, as well as within 12weeks for ALND
(Table 3).
Matched comparison of the two groups
Following PSM of patients with an equal likelihood of
receiving IBR based on patient and tumour characteristics,
women who had IBR were still less likely to receive adju-
vant chemotherapy within 6weeks (OR 0⋅95, 95 per cent
c.i. 0⋅90 to 0⋅99; P= 0⋅035), but not within 9weeks (OR
0⋅97, 0⋅95 to 1⋅00; P= 0⋅050) or 12weeks (OR 1⋅00, 0⋅99
to 1⋅01; P= 0⋅894).
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Fig. 2 Proportion of women receiving adjuvant chemotherapy within 6, 9 and 12 weeks in relation to year of diagnosis
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Table 3 Univariable and multivariable analyses without propensity score matching of characteristics associated with time to adjuvant
chemotherapy within 6, 9 and 12 weeks
Time to adjuvant chemotherapy
≤6weeks ≤9weeks ≤12weeksNo. of
patients
(n=6300)*
OR
(univariable)
OR
(multivariable)
OR
(univariable)
OR
(multivariable)
OR
(univariable)
OR
(multivariable)
IBR after mastectomy
No 4600 (73⋅0) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference)
Yes 1700 (27⋅0) 0⋅82 (0⋅72, 0⋅92) 0⋅76 (0⋅66, 0⋅87) 0⋅79 (0⋅64, 0⋅98) 0⋅69 (0⋅54, 0⋅87) 1⋅09 (0⋅72, 1⋅64) 0⋅75 (0⋅48, 1⋅17)
Year of diagnosis
2012 1572 (25⋅0) 1⋅00 (reference) – 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference)
2013 1478 (23⋅5) 1⋅03 (0⋅88, 1⋅21) – 0⋅96 (0⋅73, 1⋅26) 0⋅95 (0⋅72, 1⋅25) 1⋅28 (0⋅80, 2⋅05) 1⋅30 (0⋅81, 2⋅08)
2014 1365 (21⋅7) 1⋅12 (0⋅95, 1⋅31) – 1⋅11 (0⋅83, 1⋅48) 1⋅05 (0⋅78, 1⋅42) 1⋅53 (0⋅92, 2⋅55) 1⋅50 (0⋅90, 2⋅50)
2015 1101 (17⋅5) 0⋅99 (0⋅83, 1⋅17) – 1⋅43 (1⋅03, 1⋅99) 1⋅47 (1⋅04, 2⋅07) 2⋅49 (1⋅31, 4⋅75) 2⋅44 (1⋅26, 4⋅70)
2016 784 (12⋅4) 0⋅91 (0⋅76, 1⋅09) – 0⋅94 (0⋅68, 1⋅31) 0⋅85 (0⋅60, 1⋅20) 1⋅63 (0⋅87, 3⋅05) 1⋅52 (0⋅80, 2⋅89)
Age (years)
<40 599 (9⋅5) 1⋅13 (0⋅92, 1⋅39) 1⋅17 (0⋅94, 1⋅46) 1⋅17 (0⋅79, 1⋅72) 1⋅17 (0⋅78, 1⋅75) 1⋅23 (0⋅56, 2⋅66) 1⋅28 (0⋅59, 2⋅79)
40–49 1659 (26⋅3) 1⋅18 (1⋅02, 1⋅37) 1⋅20 (1⋅03, 1⋅40) 1⋅24 (0⋅94, 1⋅63) 1⋅21 (0⋅92, 1⋅60) 0⋅93 (0⋅57, 1⋅54) 0⋅94 (0⋅57, 1⋅55)
50–59 2084 (33⋅1) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference)
60–69 1642 (26⋅1) 0⋅78 (0⋅68, 0⋅93) 0⋅68 (0⋅59, 0⋅79) 0⋅72 (0⋅56, 0⋅91) 0⋅64 (0⋅49, 0⋅82) 0⋅60 (0⋅38, 0⋅95) 0⋅57 (0⋅36, 0⋅89)
≥70 316 (5⋅0) 0⋅71 (0⋅55, 0⋅91) 0⋅51 (0⋅39, 0⋅67) 0⋅82 (0⋅53, 1⋅28) 0⋅62 (0⋅39, 0⋅99) 0⋅73 (0⋅32, 1⋅67) 0⋅68 (0⋅30, 1⋅56)
WHO performance status
0 5698 (90⋅4) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) –
1 566 (9⋅0) 0⋅62 (0⋅52, 0⋅74) 0⋅62 (0⋅51, 0⋅75) 0⋅63 (0⋅47, 0⋅85) 0⋅63 (0⋅46, 0⋅85) 0⋅75 (0⋅43, 1⋅31) –
≥2 36 (0⋅6) 0⋅44 (0⋅23, 0⋅86) 0⋅51 (0⋅25, 1⋅02) 0⋅35 (0⋅14, 0⋅84) 0⋅39 (0⋅15, 0⋅98) 0⋅32 (0⋅08, 1⋅36) –
Histology
No special type 4994 (79⋅3) 1⋅00 (reference) – 1⋅00 (reference) – 1⋅00 (reference) –
Lobular 899 (14⋅3) 0⋅96 (0⋅82, 1⋅12) – 1⋅04 (0⋅78, 1⋅38) – 1⋅67 (0⋅89, 3⋅12) –
Both/other 407 (6⋅5) 0⋅86 (0⋅69, 1⋅06) – 0⋅80 (0⋅55, 1⋅15) – 0⋅82 (0⋅42, 1⋅58) –
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Table 3 Continued
Time to adjuvant chemotherapy
≤6weeks ≤9weeks ≤12weeksNo. of
patients
(n=6300)*
OR
(univariable)
OR
(multivariable)
OR
(univariable)
OR
(multivariable)
OR
(univariable)
OR
(multivariable)
DCIS component
No 2864 (45⋅5) 1⋅00 (reference) – 1⋅00 (reference) – 1⋅00 (reference) –
Yes 3436 (54⋅5) 0⋅99 (0⋅89, 1⋅11) – 0⋅90 (0⋅74, 1⋅10) – 0⋅89 (0⋅62, 1⋅28) –
Receptor status
Triple-negative 918 (14⋅6) 1⋅34 (1⋅14, 1⋅58) 1⋅12 (1⋅03, 1⋅22) 1⋅33 (0⋅99, 1⋅80) 0⋅96 (0⋅69, 1⋅35) 0⋅79 (0⋅49, 1⋅29) –
HER-2+ 1458 (23⋅1) 1⋅34 (1⋅17, 1⋅53) 1⋅17 (1⋅09, 1⋅26) 1⋅43 (1⋅11, 1⋅85) 1⋅19 (0⋅91, 1⋅57) 1⋅12 (0⋅71, 1⋅77) –
HR+/HER2− 3765 (59⋅8) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) –
Unknown 159 (2⋅5) 1⋅50 (1⋅03, 2⋅17) 1⋅94 (1⋅70, 2⋅22) 1⋅39 (0⋅70, 2⋅74) 1⋅51 (0⋅75, 3⋅06) 1⋅01 (0⋅32, 3⋅25) –
Differentiation grade
Well 592 (9⋅4) 0⋅70 (0⋅58, 0⋅84) 0⋅90 (0⋅73, 1⋅11) 0⋅55 (0⋅40, 0⋅75) 0⋅68 (0⋅48, 0⋅96) 0⋅61 (0⋅35, 1⋅05) –
Moderate 2927 (46⋅5) 0⋅83 (0⋅74, 0⋅93) 0⋅94 (0⋅85, 1⋅11) 0⋅71 (0⋅57, 0⋅88) 0⋅81 (0⋅64, 1⋅03) 1⋅05 (0⋅72, 1⋅55) –
Poor 2781 (44⋅1) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) –
Tumour stage
I 1771 (28⋅1) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) –
IIa 2174 (34⋅5) 1⋅08 (0⋅94, 1⋅24) 1⋅44 (1⋅24, 1⋅68) 1⋅12 (0⋅87, 1⋅45) 1⋅51 (1⋅14, 2⋅00) 1⋅38 (0⋅87, 2⋅20) –
IIb 1056 (16⋅8) 0⋅72 (0⋅61, 0⋅84) 1⋅30 (1⋅06, 1⋅60) 0⋅73 (0⋅55, 0⋅97) 1⋅34 (0⋅94, 1⋅90) 0⋅99 (0⋅58, 1,66) –
III 1256 (19⋅9) 1⋅11 (0⋅94, 1⋅30) 1⋅72 (1⋅37, 2⋅15) 0⋅90 (0⋅67, 1⋅19) 1⋅43 (0⋅98, 2⋅09) 1⋅03 (0⋅63, 1⋅70) –
IV 43 (0⋅7) 0⋅52 (0⋅28, 0⋅95) 0⋅65 (0⋅34, 1⋅25) 2⋅97 (0⋅41, 21⋅78) 3⋅76 (0⋅50, 28⋅18) – –
Sentinel node biopsy
No 1570 (24⋅9) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) –
Yes 4730 (75⋅1) 0⋅51 (0⋅44, 0⋅58) 0⋅23 (0⋅19, 0⋅27) 0⋅59 (0⋅46, 0⋅77) 0⋅33 (0⋅24, 0⋅45) 0⋅85 (0⋅56, 1⋅31) –
ALND
No 3568 (56⋅6) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference)
Yes 2732 (43⋅4) 0⋅57 (0⋅51, 0⋅63) 0⋅23 (0⋅19, 0⋅27) 0⋅53 (0⋅44, 0⋅65) 0⋅30 (0⋅23, 0⋅39) 0⋅56 (0⋅39, 0⋅81) 0⋅58 (0⋅40, 0⋅85)
Hospital transfer†
Same hospital 6098 (96⋅8) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) – 1⋅00 (reference) –
Different hospital 202 (3⋅2) 0⋅55 (0⋅42, 0⋅73) 0⋅48 (0⋅36, 0⋅66) 0⋅75 (0⋅45, 1⋅22) – 0⋅98 (0⋅36, 2⋅67) –
Hospital volume of surgery
(no. of patients)
1–99 252 (4⋅0) 0⋅91 (0⋅67, 1⋅23) 0⋅94 (0⋅68, 1⋅30) 1⋅37 (0⋅70, 2⋅70) 1⋅40 (0⋅70, 2⋅79) 1⋅37 (0⋅40, 4⋅65) –
100–149 1299 (20⋅6) 0⋅88 (0⋅74, 1⋅04) 0⋅87 (0⋅72, 1⋅04) 0⋅70 (0⋅51, 0⋅97) 0⋅71 (0⋅51, 0⋅99) 0⋅70 (0⋅40, 1⋅24) –
150–199 1231 (19⋅5) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) –
200–249 714 (11⋅3) 0⋅96 (0⋅78, 1⋅20) 0⋅61 (0⋅76, 1⋅18) 0⋅68 (0⋅47, 0⋅98) 0⋅69 (0⋅47, 1⋅00) 0⋅60 (0⋅32, 1⋅14) –
≥250 2804 (44⋅5) 0⋅76 (0⋅66, 0⋅89) 0⋅75 (0⋅66, 0⋅87) 0⋅72 (0⋅54, 0⋅96) 0⋅76 (0⋅57, 1⋅02) 0⋅91 (0⋅54, 1⋅54) –
Values in parentheses are 95 per cent confidence intervals unless indicated otherwise; *values are number (per cent). †Between surgery and adjuvant
chemotherapy. IBR, immediate breast reconstruction; DCIS, ductal carcinoma in situ; HR+, hormone receptor-positive; ALND, axillary lymph node
dissection.
Discussion
This large population-based study, analysing patients
from all hospitals treating breast cancer in the Nether-
lands, found that, compared with mastectomy alone,
IBR after mastectomy reduced the likelihood of receiv-
ing adjuvant chemotherapy within 6weeks of surgery,
as recommended by Dutch6 and European4,5 guide-
lines, but not within 9 or 12weeks. This suggests that
postmastectomy IBR is not necessarily contraindicated in
patients who need adjuvant chemotherapy, because in gen-
eral IBR does not delay its initiation to a clinically relevant
extent.
Previous studies on the impact of IBR on time to adjuvant
chemotherapy reported a large variation in time to adjuvant
chemotherapy, ranging from 21 to 80 days for those who
had mastectomy alone and from 31 to 97 days for patients
who received IBR30–34, with reported differences between
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on behalf of BJS Society Ltd.
Immediate breast reconstruction after mastectomy and the timing of adjuvant chemotherapy
these cohorts of 14–27 days24. However, this large varia-
tion may have been the result of the small single-centre
studies, weak methodology and biases, such as the lack of
adjusting for treatment by indication bias.
The findings of the present study are not in line with
the recently published results from a large multicentre
study of Jabo and colleagues35 in the USA, which suggested
that IBR delays time from diagnosis to treatment but not
from surgery to adjuvant chemotherapy. This discrepancy
may be explained by differences in the statistical approach,
as these authors used time as a continuous value, com-
pared with a categorical value in the present study. More-
over, Jabo and co-workers35 compared time from surgery
to adjuvant chemotherapy with non-parametric tests with-
out adjusting for confounders, because the latter was not
the main focus of their study. It is noteworthy that their
reported time from surgery to adjuvant chemotherapy was
considerably longer than that found in the present study,
both for patients who had mastectomy alone (40 versus
34 days respectively) and those who underwent IBR (42 ver-
sus 36 days)35.
The present study suggests that patients who had sentinel
node biopsy or ALND were less likely to receive adju-
vant chemotherapy within the predefined cut-off points,
confirming the previously reported delaying impact of
ALND34. In the present study, postoperative complications
may have occurred more frequently in patients who under-
went ALND combined with postmastectomy IBR, and
thereby potentially could have delayed chemotherapy36–38.
Postoperative complications, such as axillary seroma, are
common after mastectomy combined with ALND. The
present study suggests that the associated risk of postoper-
ative complications after sentinel node biopsy and ALND
may increase the likelihood of delay. The risk of seroma for-
mation can be reduced by minimizing dead space through
quilting sutures or an axillary drain39. Complications, and
strategies to prevent their occurrence, are not collected in
the NBCA database and could therefore not be studied as
a potential explanatory factor.
The present study has shown that patients diagnosedwith
triple-negative breast cancer, human epidermal growth fac-
tor receptor 2-positive breast cancer and higher stage dis-
ease were more likely to receive adjuvant chemotherapy
within 6weeks. It is reassuring that these tumour char-
acteristics were predictive of timely initiation of adjuvant
chemotherapy, as previous studies7,10 have shown that delay
is of particular relevance in women with thesemore aggres-
sive types of cancer.
It was expected that the impact of IBR on time to adjuvant
chemotherapy would change after adjusting for treatment
by indication bias, as the present results and a previous
Dutch study40 both showed that patients undergoing
IBR differ in many characteristics from those undergoing
mastectomy alone.
The majority of patients in the present study underwent
a two-stage implant IBR with a tissue expander. This type
of IBR is the most common approach in patients eligi-
ble for postoperative radiotherapy in most industrialized
countries41. Despite autologous reconstructions being used
increasingly in the last decade18, the proportions of differ-
ent types of IBR were comparable between the predefined
cut-off points (data not shown). Nonetheless, the number
of women who had IBR using autologous tissue with or
without a prosthesis was low (less than 8 per cent), reflect-
ing practice in the past. Therefore, a future studywithmore
patients receiving IBR using autologous tissue could inves-
tigate whether this will affect the results.
Patients who changed hospital after surgery were less
likely to receive adjuvant chemotherapy within 6weeks, but
not within 9 or 12weeks. Although this concerned only
3⋅2 per cent of all patients, the association corroborates the
theory that hospital transfer delays treatment, as shown by
previous studies34,42,43.
The present results are inconclusive regarding the asso-
ciation between hospital volume and time to adjuvant
chemotherapy. On the one hand, higher volume reduced
the likelihood of receiving adjuvant chemotherapy within
6weeks, but on the other hand, lower volume reduced
the likelihood of receiving adjuvant chemotherapy within
9weeks. A recent study by Schreuder and co-workers44
demonstrated that hospital volume only partly explains the
use of IBR in the Netherlands. Presumably, other hospi-
tal related factors such as theatre availability or number of
medical specialists have more impact on time to adjuvant
chemotherapy after IBR than just hospital volume.
The number of patients aged 70 years or above seems
lower in the present study than in previous studies. This
might be explained by the fact that adjuvant chemother-
apy is used less frequently in these older women in the
Netherlands45. Furthermore, postmastectomy IBR is used
less frequently in this patient group in the Netherlands40.
There were several limitations to the present study. First,
it was observational, using PSM to adjust for confounding
as best as possible. However, matching may be improved
by adding other factors potentially associated with delay
of adjuvant chemotherapy or the type of surgery (such
as radiotherapy, BMI, travel distance). Unfortunately, it
was not possible to include these factors as these are not
registered in the NBCA database. Insurance coverage was
probably not important in the present study, in contrast
to studies from the USA, because all Dutch patients are
obliged to have basic insurance coverage, providing equal
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access to breast cancer treatment and breast reconstruc-
tion. Second, treatment delay or choice for a specific type
of surgery can also be the result of patient preference,
such as seeking a second opinion or personal scheduling
limitations. Third, this study focused on the time between
surgery and initiation of adjuvant chemotherapy, and was
therefore not able to assess the potential delaying impact
of IBR in the preoperative phase owing to organizational
factors such as planning.
The results of the present study in a population-based
setting, which were adjusted for confounding and treat-
ment by indication bias, add to the evidence in current
literature that IBR is not contraindicated in patients who
require a mastectomy and adjuvant chemotherapy, because
it does not generally delay time to adjuvant chemotherapy
to a clinically relevant extent.
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